Siga Technologies Inc. (NASDAQ: SIGA - Get Free Report) was the target of unusually large options trading on Wednesday. Traders bought 1,200 call options on the company. This is an increase of approximately 1,438% compared to the typical volume of 78 call options. Wall Street Analyst Weigh In A number of analysts recently commented on the
Siga Technologies (NASDAQ: SIGA - Get Free Report) and Takeda Pharmaceutical (NYSE: TAK - Get Free Report) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, earnings, dividends, profitability, valuation and risk. Analyst Recommendations This is a summary of current
Siga Technologies Inc. (NASDAQ: SIGA - Get Free Report) saw some unusual options trading on Wednesday. Traders purchased 1,200 call options on the stock. This represents an increase of approximately 1,438% compared to the typical daily volume of 78 call options. Institutional Inflows and Outflows Institutional investors and hedge funds have recently added to or reduced
Aviva PLC trimmed its holdings in Siga Technologies Inc. (NASDAQ: SIGA) by 51.7% in the undefined quarter, according to its most recent disclosure with the SEC. The firm owned 51,144 shares of the company's stock after selling 54,717 shares during the period. Aviva PLC owned approximately 0.07% of Siga Technologies worth $333,000 at
SIGA Technologies, Inc. ( SIGA ) Q3 2025 Earnings Call November 6, 2025 4:30 PM EST Company Participants Diem Nguyen - CEO & Director Daniel Luckshire - Executive VP, CFO & Secretary Conference Call Participants Jyoti Prakash - Edison Investment Research Limited Presentation Operator Welcome to the SIGA Business Update Call. Before we turn the call over to SIGA management, please note that any forward-looking statements made during this call are based on management's current expectations and observations and are subject to risks and uncertainties that could cause actual results to differ from the forward-looking statements.
NEW YORK, Nov. 06, 2025 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (Nasdaq: SIGA), a commercial-stage pharmaceutical company, today reported financial results for the three and nine months ended September 30, 2025. “We continue to advance SIGA's key priorities while generating $86 million in product revenues and $33 million in pre-tax operating income for the first nine months of 2025," stated Diem Nguyen, Chief Executive Officer.
NEW YORK, Oct. 30, 2025 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (Nasdaq: SIGA), a commercial-stage pharmaceutical company, today announced that management will host a webcast and conference call to provide a business update at 4:30 P.M. ET on Thursday, November 6, 2025. Participating in the call will be Diem Nguyen, Chief Executive Officer, and Daniel Luckshire, Chief Financial Officer.
ALPHARETTA, Ga.--(BUSINESS WIRE)--Agilysys, Inc. (Nasdaq: AGYS), a leading global provider of hospitality software and services, today announced that the Saskatchewan Indian Gaming Authority (SIGA) has chosen Agilysys InfoGenesis POS and Agilysys Eatec inventory and procurement solutions for enterprise-wide use across all seven of its casino properties in Saskatchewan. This milestone represents a major advancement in SIGA's strategy to modernize its operations at scale. This modernization initi.
Healthcare stocks haven't moved since the April lows. As contrarian investors, this neglect piques our interest.
SIGA's investment thesis is overwhelmingly tied to the renewal of the BARDA contract, which remains highly uncertain due to political and budgetary risks. Recent revenue growth and a strong balance sheet are positives, but the company faces label risk in the EU and heavy reliance on U.S. government funding. Potential catalysts include TPOXX label expansion for post-exposure prophylaxis and a new BARDA contract, while EU label changes and U.S. defunding are key risks.
